Vagus Nerve Stimulation Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
LivaNova touts CMS trial clearance for vagus nerve depression treatment system
LivaNova (NSDQ:LIVN) said on Wednesday that the U.S. Centers for Medicare & Medicaid Services finalized a National Coverage Decision for LivaNova’s Vagus Nerve Stimulation Therapy for treating treatment-resistant depression. The London-based company said that the modified NCD will enable Medicare coverage for VNS therapy through the Coverage with Evidence Development framework when offered through a CMS-approved, double-blind, randomized, placebo-controlled trial with a follow-up of at least 1 year. “As part of our commitment to improving the lives of patients around the world, LivaNova requested that CMS ...
Source: Mass Device - February 21, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Neurological LivaNova Source Type: news
fMRI gauges procedure to reduce PTSD pain
Could vagus nerve stimulation help ease pain from post-traumatic stress disorder...Read more on AuntMinnie.comRelated Reading: fMRI helps finds brain biomarkers linked to severe PTSD MRI could play role in curing digestive disorders fMRI shows dehydration's effect on the brain fMRI shows how game therapy 'rewires' ADHD brains fMRI shows how mindfulness training can help veterans (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 13, 2019 Category: Radiology Source Type: news
How Can Medtech Help with the Opioid Crisis?
Pain control is one of the biggest challenges facing America today, believes Dr. Peter Staats, co-founder and chief medical officer of electroCore. Chronic pain is an ongoing, debilitating problem for many patients, but for some, overuse of opioid treatments has led to addiction. Such a condition has led to an increasing number of U.S. deathsâone studyÂ published in the JAMA Network Open1Â found that the percentage of all U.S. deaths attributable to opioids increased 292% between 2001 and 2016. This same study reported that in 2016, 20% of deaths of adults aged 24 to 35 years involve...
Source: MDDI - January 18, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Business Source Type: news
ElectroCore wins 5-year GammaCore federal supply deal
ElectroCore said yesterday it won a five-year Federal Supply Schedule Medical Equipment and Supply Contract with the U.S. Federal Government. Through the newly awarded contract, the Basking Ridge, N.J.-based company will supply its GammaCore non-invasive vagus nerve stimulation therapy to the Dept. of Veteran’s Affairs, the Dept. of Defense, the Bureau of Prisons, Indian Health Services and Public Health Services. The Basking Ridge, N.J.-based company’s GammaCore device is a non-invasive, hand-held vagus nerve stimulation device designed for the reduction of pain. The system is intended to be applied to the neck a...
Source: Mass Device - January 3, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neurological electroCore Source Type: news
ElectroCore wins cluster headache FDA 510(k) indication for GammaCore
ElectroCore said today that it won expanded FDA 510(k) clearance for its GammaCore non-invasive vagus nerve stimulation therapy, now cleared for adjunctive use for the preventive treatment of cluster headaches in adult patients. The Basking Ridge, N.J.-based company’s GammaCore device is a non-invasive, hand-held vagus nerve stimulation device designed for the reduction of pain. The system is intended to be applied to the neck and applies a patented electrical stimulation through the skin to activate the vagus nerve. The expanded approval was supported by results from two studies which demonstrated the safety and effica...
Source: Mass Device - November 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Featured Food & Drug Administration (FDA) Neurological Regulatory/Compliance electroCore Source Type: news
CMS wants clinical trial for LivaNova ’ s neurostim depression device
The U.S. Centers for Medicare & Medicaid Services has proposed the launch of a clinical trial testing out LivaNova‘s (NSDQ:LIVN) Vagus Nerve Stimulation therapy system intended to treat Treatment-Resistant Depression as it looks to adjust its National Coverage Determination for the device. The London-based medtech company said that with CMS’ proposal to change the NCD for VNS Therapy, the agency could initiate coverage through its Coverage with Evidence Development as part of a CMS-approved study. The proposed study would be a double-blinded, randomized, placebo-controlled trial with a follow-up duration o...
Source: Mass Device - November 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Neurological Neuromodulation/Neurostimulation LivaNova Source Type: news
VNS With Upper Limb Rehabilitation After Chronic Stroke VNS With Upper Limb Rehabilitation After Chronic Stroke
Is vagus nerve stimulation a useful adjunct to standard rehabilitation for improving arm function after chronic ischemic stroke?Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 19, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Can LivaNova Succeed Where Others Have Failed in HF?
LivaNova continues to live up to the promise it made to shareholders that it would focus more on its neuromodulation and cardiac surgery businesses. Through the VITARIA neuromodulation technology, the London and Houston, TX-based firm is fulfilling that promise with one device and one fell swoop. âWe clearly talk about ourselves as a company focused on the head and the heart,â Edward Andrle, LivaNovaâs General Manager of Neuromodulation, told MD+DI. âWhatâs interesting about this therapy is that it is a neuromodulation therapy. But th...
Source: MDDI - September 18, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Cardiovascular Source Type: news
LivaNova launches pivotal study for Vitaria heart failure device
LivaNova (NSDQ:LIVN) said today that it launched a pivotal study of its Vitaria neuromodulation implant for treating heart failure. The 800-patient Anthem-HFrEF study’s first subject was implanted with the Vitaria vagus nerve stimulation device at St. Luke’s Hospital in Cedar Rapids, Iowa, the London-based company said. Patients enrolled in the trial are slated to be randomized on a two-to-one ratio to be implanted with Vitaria or standard medical treatment. The primary endpoints are the event-free rate at 90 days from all device- and implantation-related serious adverse events and the composite rate of cardi...
Source: Mass Device - September 18, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Featured Neuromodulation/Neurostimulation LivaNova Source Type: news
Depression Treatment: Where We Are Missing the Mark
Depression affects 450 million people worldwide and 15 million adults in the United States (U.S.) alone. Suicide is the 10th leading cause of death in the United States, claiming over 40,000 lives every year. We see these heartbreaking stories making headlines too often, and there are tens of thousands more we do not know about. The scariest part? There is no end in sight. Antidepressants are one of the three most commonly used therapeutic drug classes in the United States. Approximately 1 in 9 Americans of all ages reported taking at least one antidepressant medication — a number that was less than 1 in 50 just th...
Source: Psych Central - September 7, 2018 Category: Psychiatry Authors: Sachin Mehta, M.D. Tags: Antidepressants Bipolar Depression Medications Mood Stabilizers Neuroscience Suicide Treatment Deep brain stimulation Deep transcranial magnetic stimulation Depression Treatment Electroconvulsive Therapy Major Depressive Disorder Source Type: news
LivaNova launches global study of epilepsy treatment
The first patient with drug-resistant epilepsy has received LivaNova’s (NASDAQ:LIVN) vagus nerve stimulation (VNS) therapy system, kicking off enrollment of a global registry to evaluate it, the company said. Drug-resistant epilepsy (DRE) affects nearly one in three people with epilepsy, according to an article in the New England Journal of Medicine. The LivaNova study will enroll up to 2,000 patients with five-year follow-up data, yielding one of the largest data sets in the world for DRE patients treated with various generations of VNS therapy. Data from the CORE-VNS study will contribute to the body of research relate...
Source: Mass Device - August 24, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Implants Neuromodulation/Neurostimulation Research & Development LivaNova Source Type: news
Medical News Today: Severe depression: Vagus nerve stimulator improves lives
A new study shows that vagus nerve stimulation, when added to medication, can drastically improve the lives of people with treatment-resistant depression. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 24, 2018 Category: Consumer Health News Tags: Depression Source Type: news
Depressed patients see quality of life improve with nerve stimulation
(Washington University School of Medicine) A national study led by researchers at Washington University School of Medicine in St. Louis indicates that people treated with vagus nerve stimulation experience significant improvements in quality of life, even when their depression symptoms don't completely dissipate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 21, 2018 Category: International Medicine & Public Health Source Type: news
ElectroCore inks nVNS neuroinflammatory response research deal with MGH
ElectroCore said yesterday it inked a collaborative research deal with Massachusetts General Hospital exploring the use of ElectroCore’s non-invasive vagus nerve stimulation tech in targeted treatments for neuroinflammation. The Basking Ridge, N.J.-based company said that investigators will examine the effects the nVNS system has on neuroinflammatory mechanisms associated with conditions in the central nervous system including pain, trauma and neurodegeneration. ElectroCore said it will supply up to $1 million through a research grant over four years to support preclinical trials of the device, including work alread...
Source: Mass Device - August 10, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Neurological Neuromodulation/Neurostimulation electroCore Source Type: news